We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Role of Heparin in Poor Responders Undergoing In Vitro Fertilisation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01315093
Recruitment Status : Recruiting
First Posted : March 15, 2011
Last Update Posted : April 7, 2016
Information provided by (Responsible Party):

Study Description
Brief Summary:
The addition of heparin increases pregnancy outcome parameters in poor responders undergoing In Vitro Fertilisation (IVF)

Condition or disease Intervention/treatment Phase
Infertility Drug: Heparin, Low-Molecular-Weight Drug: no heparin Phase 2 Phase 3

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Study Start Date : November 2010
Estimated Primary Completion Date : June 2016
Estimated Study Completion Date : June 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Blood Thinners
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: Heparin, Low-Molecular-Weight group
LMWH was administered during an IVF cycle using either the GnRH - agonist or antagonist protocol in poor responders. Drug was started at the beginning of the cycle and stopped at the time of pregnancy test if negative, or continued if pregnancy occurred until the 32th weeks of gestation
Drug: Heparin, Low-Molecular-Weight
Heparin from start till hcg test
Active Comparator: Non Heparin, Low-Molecular-Weight group
IVF cycle using either the GnRH - agonist or antagonist protocol in poor responders.
Drug: no heparin

Outcome Measures

Primary Outcome Measures :
  1. no of oocytes retrieved [ Time Frame: egg recovery, 2 years ]
    >2 between groups

Secondary Outcome Measures :
  1. clinical pregnancy rate [ Time Frame: 2 years ]
    Presence of fetal heart at transvaginal ultrasound at 6+2 gestational weeks

  2. live birth rate [ Time Frame: 2 years ]
    >20 weeks of gestation

  3. cancellation rate [ Time Frame: before ET, 2 years ]
  4. miscarriage rate [ Time Frame: 2 years ]
    pregnancy loss <20 weeks

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   25 Years to 43 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • poor responders (age>40, abnormal ovarian test, </=4 oocytes in previous cycle with conventional stimulation)
  • infertility, indication for IVF
  • no contraindications for heparin
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01315093

Contact: Charalampos S Siristatidis, Ass Professor 6932294994 ext 0030 harrysiri@yahoo.gr

3rd Department of Obstetrics & Gynecology Recruiting
Athens, Chaidari, Greece, 12642
Contact: Siristatidis       harrysiri@yahoo.gr   
Sub-Investigator: Charalampos Chrelias, Ass Professor         
Sub-Investigator: Dimitrios Kassanos, Ass Professor         
Sponsors and Collaborators
National and Kapodistrian University of Athens
More Information

Responsible Party: Siristatidis Charalampos, MD, PhD, Assistant Professor, Director of the ARU, National and Kapodistrian University of Athens
ClinicalTrials.gov Identifier: NCT01315093     History of Changes
Other Study ID Numbers: 123456
First Posted: March 15, 2011    Key Record Dates
Last Update Posted: April 7, 2016
Last Verified: March 2016

Keywords provided by Siristatidis Charalampos, MD, PhD, National and Kapodistrian University of Athens:
In Vitro Fertilisation
poor responders

Additional relevant MeSH terms:
Genital Diseases, Male
Genital Diseases, Female
Calcium heparin
Heparin, Low-Molecular-Weight
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action